Market Overview:
The global oligodendroglioma treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of oligodendroglioma, rising awareness about available treatments, and technological advancements in the field of cancer treatment. Based on type, the global oligodendroglioma treatment market can be segmented into alisertib, bevacizumab, CDX-1401, dasatinib, DCVax-L,, IMA-950 and others. Alisertib is expected to dominate this market during the forecast period owing to its high efficacy and safety profile. Based on application, the global oligodendroglioma treatment market can be segmented into clinic setting,, hospital setting and ASCs (ambulatory surgical centers). The clinic setting is expected to dominate this market duringthe forecast period owingtoits higher adoption rates across regions. Geographically,.
Product Definition:
Oligodendrogliomas are tumors that form in the brain or spinal cord from cells called oligodendrocytes. Oligodendrocytes normally help nerve cells function and survive. Treatment for oligodendroglioma may include surgery, radiation therapy, and chemotherapy.
Alisertib:
Alisertib (Zirabev) is an immuno-oncology drug developed by Zirabev, a member of the Roche group. It is indicated for the treatment of patients with oligodendroglioma and rhabdomyosarcoma. Oligodendroglioma or more commonly known as brain tumor is one of the most common malignantancies in adults accounting for nearly half of all intracranial tumors worldwide.
Bevacizumab:
Bevacizumab is a drug that interferes with the growth of cancer cells. It is used in the treatment of patients with oligodendroglioma, a type of brain tumor. Oligodendroglioma accounts for about 4% to 5% of all tumors diagnosed in adults and around 0.5% to 1% among children below 15 years old worldwide.
Application Insights:
Based on application, the global oligodendroglioma treatment market is segmented into clinic, hospital and ASCs. Owing to the rising number of patients suffering from brain cancer and growing awareness about available treatment options, ASCs are anticipated to dominate the overall market throughout the forecast period.
However, owing to increasing government funding for research initiatives related to brain tumorigenesis and prevalence as well as diagnosis of oligodendrogliomas in different regions such as North America and Europe; Asia Pacific region is expected to emerge as a lucrative market for this disease over the next eight years. Owing to ongoing clinical trials involving various drugs under development by different pharmaceutical companies such as bevacizumab (Avastin) developed by Roche; imatinib (Gleevic) developed by Pfizer Inc.; pazopanib (Caprelsa) developed by Astrazeneca Plc.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017 owing to the availability of improved healthcare infrastructure, high disposable income, and rising awareness about early diagnosis in U.S. and Canada that facilitate access to novel drugs for oligodendroglioma treatment. Moreover, presence of key players such as Pfizer Inc.; Merck & Co., Inc.; Celgene Corporation; Biogen Inc.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period due to rise in healthcare expenditure by governments along with increasing prevalence of cancer that requires advanced treatments resulting from unhealthy lifestyle habits such as smoking cigarettes.
Growth Factors:
- Increasing incidence of oligodendroglioma
- Rising awareness about the disease and its treatment options
- Growing number of clinical trials for oligodendroglioma treatment
- Availability of new and innovative therapies for the treatment of oligodendroglioma
- increasing investment in research and development for the development of novel therapies for the treatment of oligodendroglioma
Scope Of The Report
Report Attributes
Report Details
Report Title
Oligodendroglioma Treatment Market Research Report
By Type
Alisertib, Bevacizumab, CDX-1401, Dasatinib, DCVax-L, IMA-950, Others
By Application
Clinic, Hospital, ASCs
By Companies
AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cavion LLC, Celldex Therapeutics Inc, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, Immatics Biotechnologies GmbH, Ipsen SA, Leadiant Biosciences Inc, AngioChem Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global Oligodendroglioma Treatment Market Report Segments:
The global Oligodendroglioma Treatment market is segmented on the basis of:
Types
Alisertib, Bevacizumab, CDX-1401, Dasatinib, DCVax-L, IMA-950, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, ASCs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AngioChem Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cavion LLC
- Celldex Therapeutics Inc
- Eli Lilly and Co
- F. Hoffmann-La Roche Ltd
- Immatics Biotechnologies GmbH
- Ipsen SA
- Leadiant Biosciences Inc
- AngioChem Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- Pfizer Inc
- Tocagen Inc
Highlights of The Oligodendroglioma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alisertib
- Bevacizumab
- CDX-1401
- Dasatinib
- DCVax-L
- IMA-950
- Others
- By Application:
- Clinic
- Hospital
- ASCs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oligodendroglioma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oligodendroglioma is a type of brain tumor that can be treated with surgery, radiation therapy, or chemotherapy.
Some of the major companies in the oligodendroglioma treatment market are AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cavion LLC, Celldex Therapeutics Inc, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, Immatics Biotechnologies GmbH, Ipsen SA, Leadiant Biosciences Inc, AngioChem Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oligodendroglioma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oligodendroglioma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oligodendroglioma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oligodendroglioma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oligodendroglioma Treatment Market Size & Forecast, 2020-2028
4.5.1 Oligodendroglioma Treatment Market Size and Y-o-Y Growth
4.5.2 Oligodendroglioma Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Alisertib
5.2.2 Bevacizumab
5.2.3 CDX-1401
5.2.4 Dasatinib
5.2.5 DCVax-L
5.2.6 IMA-950
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 ASCs
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oligodendroglioma Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oligodendroglioma Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Alisertib
9.6.2 Bevacizumab
9.6.3 CDX-1401
9.6.4 Dasatinib
9.6.5 DCVax-L
9.6.6 IMA-950
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 ASCs
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Alisertib
10.6.2 Bevacizumab
10.6.3 CDX-1401
10.6.4 Dasatinib
10.6.5 DCVax-L
10.6.6 IMA-950
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 ASCs
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Alisertib
11.6.2 Bevacizumab
11.6.3 CDX-1401
11.6.4 Dasatinib
11.6.5 DCVax-L
11.6.6 IMA-950
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 ASCs
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Alisertib
12.6.2 Bevacizumab
12.6.3 CDX-1401
12.6.4 Dasatinib
12.6.5 DCVax-L
12.6.6 IMA-950
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 ASCs
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Alisertib
13.6.2 Bevacizumab
13.6.3 CDX-1401
13.6.4 Dasatinib
13.6.5 DCVax-L
13.6.6 IMA-950
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 ASCs
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oligodendroglioma Treatment Market: Competitive Dashboard
14.2 Global Oligodendroglioma Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AngioChem Inc
14.3.2 Boehringer Ingelheim GmbH
14.3.3 Bristol-Myers Squibb Co
14.3.4 Cavion LLC
14.3.5 Celldex Therapeutics Inc
14.3.6 Eli Lilly and Co
14.3.7 F. Hoffmann-La Roche Ltd
14.3.8 Immatics Biotechnologies GmbH
14.3.9 Ipsen SA
14.3.10 Leadiant Biosciences Inc
14.3.11 AngioChem Inc
14.3.12 Northwest Biotherapeutics Inc
14.3.13 Novartis AG
14.3.14 Pfizer Inc
14.3.15 Tocagen Inc
